Known targets — ChEMBL curated mechanism
The experimentally established mechanism targets of Renzapride. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HTR3A known ✓ | P46098 | 7/20 | 0.98 |
| ▸ | HTR3E known ✓ | A5X5Y0 | 3/20 | 0.98 |
| ▸ | HTR3B known ✓ | O95264 | 3/20 | 0.98 |
| ▸ | HTR3D known ✓ | Q70Z44 | 3/20 | 0.98 |
| ▸ | HTR3C known ✓ | Q8WXA8 | 3/20 | 0.98 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.98 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.76 |
| ▸ | HTR5A | P47898 | 1/20 | 0.76 |
| ▸ | MEN1 | O00255 | 1/20 | 0.76 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.76 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.76 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.76 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.76 |
| ▸ | ADRA2A | P08913 | 1/20 | 0.60 |
| ▸ | ADRA2B | P18089 | 1/20 | 0.60 |
| ▸ | ADRA2C | P18825 | 1/20 | 0.60 |
| ▸ | HTR2A | P28223 | 1/20 | 0.60 |
| ▸ | HTR2C | P28335 | 1/20 | 0.60 |
| ▸ | HTR2B | P41595 | 1/20 | 0.60 |
| ▸ | DRD2 | P14416 | 1/20 | 0.59 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Renzapride SCHEMBL5765864 | 1.00 | HTR3A (0.98) | HTR3AHTR3EHTR3BHTR3DHTR3C | |
| Renzapride SCHEMBL5367707 | 1.00 | HTR3A (0.98) | HTR3AHTR3EHTR3BHTR3DHTR3C | |
| Renzapride SCHEMBL5767174 | 0.99 | HTR3A (0.96) | HTR3AHTR3EHTR3BHTR3DHTR3C | |
| Renzapride SCHEMBL5371617 | 0.99 | HTR3A (0.96) | HTR3AHTR3EHTR3BHTR3DHTR3C | |
| Renzapride SCHEMBL17037 | 0.99 | HTR3A (1.00) | HTR3AHTR3EHTR3BHTR3DHTR3C | |
| Renzapride SCHEMBL678616 | 0.99 | HTR3A (1.00) | HTR3AHTR3EHTR3BHTR3DHTR3C | |
| Renzapride SCHEMBL4534994 | 0.99 | HTR3A (1.00) | HTR3AHTR3EHTR3BHTR3DHTR3C | |
| Renzapride SCHEMBL1650356 | 0.97 | HTR3A (0.96) | HTR3AHTR3EHTR3BHTR3DHTR3C | |
| SCHEMBL8292934 | 0.88 | HTR3A (0.80) | HTR3AHTR3EHTR3BHTR3DHTR3C | |
| Zacopride SCHEMBL667580 | 0.88 | MAPK1 (0.98) | HTR3AHTR3EHTR3BHTR3DHTR3C |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 36 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| JP-2007514726-A | — | — | 2007-06-07 | — | — | JP | claimed |
| US-7189852-B2 | Preparing renzapride (hydrochloride) on a laboratory or industrial scale by a simplified process of forming the acyl chloride derivative of 2-(methoxy),3-acyamino,5-chlorobenzoic acid by reacting oxalyl or thionyl chloride in a solvent, e.g. dimethylformamide; coupling with 1-diazabicylo(3.3.1)nonane | ALIZYME THERAPEUTICS LIMITED (GB) | 2007-03-13 | — | — | US | claimed |
| JP-2007505089-A | — | — | 2007-03-08 | — | — | JP | claimed |
| CN-1894248-A | Synthesis of polymorph of 4-amino-5-chloro-2-methoxy-N- (1-azabicyclo [3.3.1] non-4-yl) benzamide hydrochloride hydrate | ALIZYME THERAPEUTICS LTD (GB) | 2007-01-10 | — | — | CN | claimed |
| CN-1849320-A | Process for the preparation of renzapride and intermediates thereof | ALIZYME THERAPEUTICS LTD (GB) | 2006-10-18 | — | — | CN | claimed |
| EP-1699789-A2 | SYNTHESIS OF A POLYMORPH OF 4-AMINO-5-CHLORO-2-METHOXY-N-(1-AZABICYCLO[3.3.1]NON-4-YL)BENZAMIDE HYDROCHLORIDE HYDRATE | Alizyme Therapeutics Limited (GB) | 2006-09-13 | — | — | EP | claimed |
| EP-1664048-A2 | PROCESS FOR THE PREPARATION OF RENZAPRIDE AND INTERMEDIATES THEREOF | Alizyme Therapeutics Limited (GB) | 2006-06-07 | — | — | EP | claimed |
| US-20050209271-A1 | Form of renzapride hydrochloride hydrate and uses thereof | ALIZYME THERAPEUTICS LIMITED (GB) | 2005-09-22 | — | — | US | claimed |
| WO-2005058896-A2 | SYNTHESIS OF A POLYMORPH OF 4-AMINO-5-CHLORO-2-METHOXY-N-(1-AZABICYCLO[3.3.1]NON-4-YL)BENZAMIDE HYDROCHLORIDE HYDRATE | ALIZYME THERAPEUTICS LIMITED (GB) | 2005-06-30 | — | — | WO | claimed |
| WO-2005023808-A2 | PROCESS FOR THE PREPARATION OF RENZAPRIDE AND INTERMEDIATES THEREOF | ALIZYME THERAPEUTICS LIMITED (GB) | 2005-03-17 | — | — | WO | claimed |
| US-20050049416-A1 | Synthesis | ENDOLOGIC LLC | 2005-03-03 | — | — | US | claimed |
| US-20260000674-A1 | PHARMACEUTICAL COMPOSITION | GEXVAL INC. (JP) | 2026-01-01 | — | — | US | disclosed |
| EP-4548934-A1 | PHARMACEUTICAL COMPOSITION | Gexval Inc. (JP) | 2025-05-07 | — | — | EP | disclosed |
| CN-119789869-A | Pharmaceutical composition | 嘉惟思远制药有限公司 | 2025-04-08 | — | — | CN | disclosed |
| WO-2024005132-A1 | PHARMACEUTICAL COMPOSITION | マルホ株式会社 | 2024-01-04 | — | — | WO | disclosed |
| WO-2005058896-A3 | SYNTHESIS OF A POLYMORPH OF 4-AMINO-5-CHLORO-2-METHOXY-N-(1-AZABICYCLO[3.3.1]NON-4-YL)BENZAMIDE HYDROCHLORIDE HYDRATE | ALIZYME THERAPEUTICS LTD (GB) | 2005-08-11 | — | — | WO | disclosed |
| WO-2005058896-A2 | SYNTHESIS OF A POLYMORPH OF 4-AMINO-5-CHLORO-2-METHOXY-N-(1-AZABICYCLO[3.3.1]NON-4-YL)BENZAMIDE HYDROCHLORIDE HYDRATE | ALIZYME THERAPEUTICS LIMITED (GB) | 2005-06-30 | — | — | WO | disclosed |
| WO-2005058896-A2 | SYNTHESIS OF A POLYMORPH OF 4-AMINO-5-CHLORO-2-METHOXY-N-(1-AZABICYCLO[3.3.1]NON-4-YL)BENZAMIDE HYDROCHLORIDE HYDRATE | ALIZYME THERAPEUTICS LIMITED (GB) | 2005-06-30 | — | — | WO | disclosed |
| WO-2005023808-A2 | PROCESS FOR THE PREPARATION OF RENZAPRIDE AND INTERMEDIATES THEREOF | ALIZYME THERAPEUTICS LIMITED (GB) | 2005-03-17 | — | — | WO | disclosed |
| US-20050049416-A1 | Synthesis | ENDOLOGIC LLC | 2005-03-03 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20260000674-A1 | PHARMACEUTICAL COMPOSITION | HTR4, IL4, FFAR4 | HTR3A 14/4885HTR3E 29/4885HTR3B 22/4885 |
| US-20050049416-A1 | Synthesis | ALKBH5, AZI2, ALKBH1 | HTR3A 602/4885HTR3E 953/4885HTR3B 795/4885 |
| US-20050209271-A1 | Form of renzapride hydrochloride hydrate and uses thereof | REN, ACE, AGT | HTR3A 524/4885HTR3E 792/4885HTR3B 580/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.